NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06993675 2025-08-29
ROTATE
Yale University
Phase 2 Recruiting
NCT05203003 2024-12-06
MRD-CONFIRM
Assistance Publique - Hôpitaux de Paris
Recruiting
NCT06697483 2024-11-25
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
Phase NA Recruiting
NCT06109233 2024-07-05
MRD
The First Hospital of Jilin University
Recruiting
NCT06463717 2024-06-24
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
First Affiliated Hospital of Zhejiang University
Recruiting
NCT06302699 2024-03-12
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Recruiting
NCT06158269 2023-12-06
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting